NTLA
Intellia Therapeutics, Inc. NASDAQ Listed May 6, 2016$15.67
+3.09%
vs $15.20
Mkt Cap $1.7B
52w Low $8.04
38.3% of range
52w High $27.98
50d MA $13.76
200d MA $13.47
P/E (TTM)
—
EV/EBITDA
—
P/B
2.5x
Debt/Equity
0.1x
ROE
-61.5%
P/FCF
-4.8x
RSI (14)
58.00
ATR (14)
$1.31
Beta
1.99
50d MA
$13.76
200d MA
$13.47
Avg Volume
6.9M
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
40 Erie Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 13.85 | -0.5% | -1.0% | +2.8% | +2.3% | -3.0% | +2.1% | — |
| Feb 26, 2026 | AMC | -0.99 | -0.83 | +16.2% | 14.28 | -3.1% | -3.5% | +12.0% | -11.9% | +1.5% | -4.8% | — |
| Nov 6, 2025 | AMC | -1.02 | -0.92 | +9.8% | 12.32 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% | — |
| Aug 7, 2025 | AMC | -1.03 | -0.99 | +3.9% | 11.46 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% | — |
| May 8, 2025 | AMC | -1.26 | -1.10 | +12.7% | 8.28 | +1.7% | -1.9% | +5.3% | -2.7% | -5.3% | +2.4% | — |
| Feb 27, 2025 | AMC | -1.32 | -1.24 | +6.1% | 10.86 | -5.4% | -7.1% | -6.3% | -3.7% | +3.0% | +5.7% | — |
| Nov 7, 2024 | AMC | -1.37 | -1.34 | +2.2% | 16.00 | +0.3% | +4.6% | +4.6% | -4.9% | -3.2% | -6.1% | — |
| Aug 8, 2024 | AMC | -1.21 | -1.31 | -8.3% | 22.38 | +0.1% | -4.1% | +1.4% | +2.9% | -4.0% | +6.3% | — |
| May 9, 2024 | AMC | -1.35 | -1.06 | +21.5% | 24.86 | +0.6% | -1.6% | +3.9% | +1.2% | +1.9% | -0.2% | — |
| Feb 22, 2024 | AMC | -1.47 | -1.46 | +0.7% | 27.18 | -1.7% | -4.0% | +6.0% | +12.1% | +5.7% | -2.1% | — |
| Nov 9, 2023 | AMC | -1.52 | -1.38 | +9.2% | 24.96 | +0.4% | -3.3% | -1.3% | +11.1% | +0.5% | -2.1% | — |
| Aug 3, 2023 | AMC | -1.32 | -1.40 | -6.1% | 39.09 | +1.2% | +1.3% | -1.5% | +2.5% | +0.0% | -1.2% | — |
| May 4, 2023 | AMC | -1.41 | -1.17 | +17.0% | 43.65 | +1.2% | +0.6% | -1.6% | +1.8% | +2.8% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 28 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 28 | Goldman Sachs | Maintains | Sell → Sell | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 27 | Baird | Maintains | Neutral → Neutral | — | $13.63 | $14.23 | +4.4% | -4.3% | +1.2% | -5.7% | +8.3% | -1.6% |
| Apr 27 | Chardan Capital | Maintains | Buy → Buy | — | $13.63 | $14.23 | +4.4% | -4.3% | +1.2% | -5.7% | +8.3% | -1.6% |
| Mar 4 | Jones Trading | Upgrade | Hold → Buy | — | $13.61 | $13.98 | +2.7% | +1.5% | -4.8% | +2.2% | +3.3% | -3.0% |
| Mar 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 2 | Chardan Capital | Maintains | Buy → Buy | — | $13.78 | $13.79 | +0.1% | +12.0% | -11.9% | +1.5% | -4.8% | +2.2% |
| Feb 27 | Chardan Capital | Maintains | Buy → Buy | — | $14.28 | $13.84 | -3.1% | -3.5% | +12.0% | -11.9% | +1.5% | -4.8% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.83 | $14.97 | +0.9% | -6.8% | +0.6% | -5.4% | -0.7% | -0.1% |
| Nov 12 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $10.18 | $10.02 | -1.6% | -6.8% | -8.6% | +0.3% | -2.5% | -0.1% |
| Nov 11 | Evercore ISI | Downgrade | Outperform → In Line | — | $9.73 | $9.59 | -1.4% | +4.6% | -6.8% | -8.6% | +0.3% | -2.5% |
| Nov 11 | Jones Trading | Downgrade | Buy → Hold | — | $9.73 | $9.59 | -1.4% | +4.6% | -6.8% | -8.6% | +0.3% | -2.5% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $10.71 | +12.5% | +2.2% | +4.6% | -6.8% | -8.6% | +0.3% |
| Nov 10 | Truist | Maintains | Buy → Buy | — | $9.52 | $10.71 | +12.5% | +2.2% | +4.6% | -6.8% | -8.6% | +0.3% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Wedbush | Maintains | Neutral → Neutral | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | JP Morgan | Downgrade | Neutral → Underweight | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.12 | $11.78 | -10.2% | -6.5% | +2.9% | +3.6% | -6.7% | +11.2% |
| Oct 28 | Bernstein | Downgrade | Outperform → Market Perform | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 27 | BofA Securities | Maintains | Buy → Buy | — | $25.60 | $13.73 | -46.4% | -42.2% | -5.6% | -6.0% | -6.5% | +2.9% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.60 | $13.73 | -46.4% | -42.2% | -5.6% | -6.0% | -6.5% | +2.9% |
| Oct 27 | Chardan Capital | Maintains | Buy → Buy | — | $25.60 | $13.73 | -46.4% | -42.2% | -5.6% | -6.0% | -6.5% | +2.9% |
| Oct 6 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $19.96 | $21.06 | +5.5% | +2.9% | -0.5% | +19.7% | +4.0% | -3.7% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.11 | $16.42 | +1.9% | -3.2% | +10.7% | -1.0% | +4.0% | -6.5% |
| Sep 19 | JMP Securities | Maintains | Market Perform → Market Perform | — | $16.11 | $16.42 | +1.9% | -3.2% | +10.7% | -1.0% | +4.0% | -6.5% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $10.86 | $10.99 | +1.2% | +1.3% | -0.9% | +0.8% | -2.4% | -4.1% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $10.79 | $10.92 | +1.2% | -0.5% | +1.1% | +1.3% | -0.9% | +0.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.46 | $11.51 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.46 | $11.51 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $11.46 | $11.51 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.31 | $8.54 | +2.8% | +7.8% | +6.9% | +0.2% | -4.2% | +0.3% |
| Jun 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.16 | $7.27 | +1.5% | +7.4% | -0.3% | -1.2% | +6.7% | +2.3% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.66 | $7.37 | -23.7% | -22.9% | -7.8% | +4.2% | +7.4% | -0.3% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.06 | $9.04 | -0.2% | +6.7% | -4.9% | +2.8% | -3.2% | +1.7% |
| May 19 | Wedbush | Maintains | Neutral → Neutral | — | $8.50 | $8.55 | +0.6% | +6.6% | +6.7% | -4.9% | +2.8% | -3.2% |
No insider trades available.
8-K · 8.01
!! High
Intellia Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z treating hereditary angioedema, presented at EAACI Congress and published in NEJM, potentially strengthening its regulatory approval prospects.
Jun 15
8-K
Intellia Therapeutics, Inc. -- 8-K Filing
Jun 10
8-K · 2.02
!! High
Intellia Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Intellia Therapeutics reported Q1 2026 financial results and business updates, providing investors visibility into the gene-editing biotech's operational progress and cash position.
May 11
8-K
Intellia Therapeutics, Inc. -- 8-K Filing
Intellia Therapeutics completed an underwritten public offering under its shelf registration, with standard indemnification provisions protecting underwriters from securities law liabilities.
Apr 30
8-K · 7.01
! Medium
Intellia Therapeutics, Inc -- 8-K 7.01: Regulation FD Disclosure
Intellia Therapeutics disclosed material information via press release and presentation, requiring investors to review the furnished exhibits for details on company developments or announcements.
Apr 27
8-K
Unknown — 8-K Filing
Intellia Therapeutics updated its corporate bylaws, likely reflecting governance changes that could affect shareholder voting rights, board structure, or operational procedures—investors should review specifics for potential impacts on corporate control.
Apr 10
8-K · 7.01
! Medium
Intellia Therapeutics, Inc -- 8-K 7.01: Regulation FD Disclosure
Intellia Therapeutics (NTLA) can resume its MAGNITUDE Phase 3 clinical trial for ATTR-CM treatment after the FDA lifted a clinical hold, potentially accelerating the company's path toward commercialization.
Mar 2
8-K
Intellia Therapeutics, Inc -- 8-K Filing
Intellia Therapeutics expects to submit a lonvo-z BLA for hereditary angioedema in late 2026 with anticipated U.S. launch in early 2027, while reactivating its MAGNITUDE-2 trial for nex-z in ATTR amyloidosis.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ark Investment Management Llc | 14,509,247 | $186M | Added | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 6,223,325 | $80M | New | Mar 2026 |
| 3 | D.e. Shaw & Co | 5,728,177 | $73M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 5,084,105 | $65M | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 4,705,901 | $60M | Added | Mar 2026 |
| 6 | Regeneron Pharmaceuticals, Inc. | 3,702,995 | $47M | — | Mar 2026 |
| 7 | Morgan Stanley | 4,655,704 | $42M | Reduced | Dec 2025 |
| 8 | Ubs Group Ag | 2,689,486 | $34M | Added | Mar 2026 |
| 9 | Fmr Llc | 2,067,222 | $27M | Added | Mar 2026 |
| 10 | Jupiter Asset Management Ltd | 1,781,063 | $23M | Added | Mar 2026 |
| 11 | Arrowstreet Capital, Limited Partnership | 1,397,243 | $18M | New | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 1,381,703 | $18M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 966,293 | $12M | Added | Mar 2026 |
| 14 | Capital Fund Management S.a. | 730,122 | $9M | Added | Mar 2026 |
| 15 | Aqr Capital Management Llc | 630,529 | $8M | Added | Mar 2026 |
| 16 | Marex Group Plc | 623,600 | $8M | — | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 579,430 | $7M | Reduced | Mar 2026 |
| 18 | Raymond James Financial Inc | 576,930 | $7M | Added | Mar 2026 |
| 19 | Susquehanna International Group, Llp | 521,465 | $7M | Reduced | Mar 2026 |
| 20 | Iq Eq Fund Management (Ireland) Ltd | 731,421 | $7M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.70B
Enterprise Value
$1.32B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.09x
P/B
2.53x
P/S
25.70x
P/FCF
-4.79x
EV/EBITDA
—
Shares Out
108.4M
Financials (TTM)
Revenue
$66.1M
Net Income
-$394.6M
EBITDA
-$384.6M
Free Cash Flow
-$354.7M
Op Cash Flow
-$348.9M
EPS Basic
$-3.81
EPS Diluted
$-3.54
EPS Forward
$-3.58
Gross Margin
-153.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$842.1M
Total Liab.
$170.7M
Total Equity
$671.4M
Cash
$449.9M
LT Debt
$66.8M
Book Value/Sh
$6.20
Debt/Equity
0.14x
Current Ratio
5.08
Quick Ratio
5.08
Returns & Growth
ROE
-61.5%
ROA
-49.0%
ROIC
-57.7%
Rev Growth YoY
+16.9%
EPS Growth YoY
+27.4%
Price Returns
2W
+7.5%
1M
+4.4%
3M
+2.1%
6M
+56.5%
12M
+104.8%
Technicals
52W High
$27.98
52W Low
$8.04
50d MA
$13.76
200d MA
$13.47
RSI (14)
58.00
ATR (14)
$1.31
Beta
1.99
Avg Volume
6.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.88
High
$35.00
Low
$8.00
Median
$20.00
Data updated apr 26, 2026 3:59pm
· Source: financialmodelingprep.com